Immunoblotting analyses demonstrated that CFZ could boost DOX-induced PARP and Caspase 3 (or Caspase 7) cleavage in all subtypes of breast cancer cell lines tested (Figure 5a-5g). The gene discussed is CASP3; the disease is breast carcinoma.